Holen Sie sich die Stockscreener-App
1.29
0.77%
-0.01
Handel nachbörslich:
1.30
0.01
+0.78%
Schlusskurs vom Vortag:
$1.30
Offen:
$1.3
24-Stunden-Volumen:
1.23M
Relative Volume:
1.01
Marktkapitalisierung:
$321.59M
Einnahmen:
$14.56M
Nettoeinkommen (Verlust:
$-63.37M
KGV:
-4.6353
EPS:
-0.2783
Netto-Cashflow:
$-19.44M
1W Leistung:
+7.50%
1M Leistung:
-16.77%
6M Leistung:
-24.56%
1J Leistung:
+84.63%
1-Tages-Spanne:
$1.27
$1.34
1-Wochen-Bereich:
$1.20
$1.365
52-Wochen-Spanne:
$0.64
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Firmenname
Lineage Cell Therapeutics Inc
Sektor
Branche
Telefon
510-871-4188
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.29 | 324.09M | 14.56M | -63.37M | -19.44M | -0.2783 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Eingeleitet | Craig Hallum | Buy |
| 2022-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-08-19 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-03-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
Promising Penny Stocks To Consider In May 2026 - simplywall.st
Lineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61 - MSN
Lineage reports positive 36-month findings on GA cell therapy - Eyes On Eyecare
Earnings Preview: LCTX to Report Financial Results Post-market on May 12 - Moomoo
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Investing News Network
Lineage Cell Therapeutics, Inc. Common Stock (NY: LCTX - FinancialContent
Lineage Cell Therapeutics, Inc. Common Stock (NYSE:LCTX) Stock Quote - FinancialContent
Lineage Cell Therapeutics Q1 Earnings Call Highlights - sharewise.com
Lineage Cell Therapeutics Q1 2026 earnings preview - MSN
Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies - Traders Union
Lineage Cell Therapeutics (LCTX) Returns To Loss In Q1 2026 Challenging Profitability Narratives - Sahm
Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses - TipRanks
Q1 2026 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call Transcript - Insider Monkey
Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing - MSN
Lineage Cell (LCTX) reports Q1 loss, lags revenue estimates - MSN
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Lineage Cell Therapeutics (LCTX) Reports Q1 2026 Earnings and St - GuruFocus
TradingKey - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highl - GuruFocus
Lineage Cell Therapeutics (LCTX) Reports Q1 Results and Advancem - GuruFocus
Is Lineage Cell Therapeutics (LCTX) Overvalued After Q1 2026 EPS - GuruFocus
Lineage Cell (LCTX) Receives Funding to Support Operations Throu - GuruFocus
LCTX: Pipeline expansion, manufacturing progress, and strong cash runway drive 2026 outlook - TradingView
LCTX: Strong pipeline expansion and robust cash position support continued clinical and manufacturing progress - TradingView
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Lineage Cell Therapeutics holds investor call after releasing first quarter 2026 results - Traders Union
LCTX: Positive clinical results, pipeline expansion, and strong cash position highlight Q1 2026 - TradingView
Lineage Cell Therapeutics (NYSE: LCTX) reports higher Q1 2026 revenue and continued R&D spend - Stock Titan
Lineage Cell Therapeutics (LCTX) posts Q1 2026 results and advances cell therapy pipeline - Stock Titan
Lineage Cell: Q1 Earnings Snapshot - WKYC
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
MSN Money - MSN
Why Lineage (LCTX) might be the best kept secret in the market (+2.55%) 2026-05-11Post Earnings - Newser
Lineage Cell Therapeutics, Inc. (LCTX) Presents at FFB Retinal Therapeutics Innovation SummitSlideshow - Seeking Alpha
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - BioSpace
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update - PharmiWeb.com
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) - Weekly Voice
CCORF Initiates Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Announces Target Price $9 - Moomoo
Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):